Every program we track, side by side — for the first time in one place. A band (how close it is to a durable cure) and an evidence tier (how solid the proof is) — always shown together, never a band alone. Full methodology here.
90–100 · leading the pack
80–89 · strong evidence, real momentum
70–79 · promising, earlier-stage evidence
60–69 · the approved comparison point
No public efficacy data yet
One patient, zero immunosuppression, insulin production still detectable past 14 months.
Full Trial Report Card →10 of 12 full-dose participants insulin-independent at one year — still requires immunosuppression.
Full Trial Report Card →No human trial yet — designed to solve cell replacement and immune evasion at once. IND targeted Q4 2026.
Full Trial Report Card →Unencapsulated, immune-evasive design — successor to discontinued CTX211. No clinical trial has started.
Program Snapshot →12 of 12 donor-islet recipients insulin-independent in a UChicago Medicine pilot — small and uncontrolled.
Full Trial Report Card →Donor-islet pouch, Phase 1/2 ongoing. Multi-year islet survival reported.
Program Snapshot →Bioprinted islet tissue, now Aspect-led after Novo Nordisk's October 2025 exit from cell therapy.
Program Snapshot →Early non-fibrotic engraftment, viable encapsulated human islets — Phase 1 interim results, January 2026.
Program Snapshot →FDA IND allowance granted for replacement-islet program SR-02.
Program Snapshot →First FDA-approved allogeneic islet therapy — the comparison point, not a competitor in the race.
Program Snapshot →Sana's next-gen candidate, developed with Mayo Clinic. No public efficacy data yet.
Program Snapshot →